GET DAILY SIGNALSWhy Is BrainsWay Ltd. (BWAY) Stock Down -6.19% Today?
Key Takeaways
- Shares of BWAY fell 6.19% to $10.92 on November 10, from a prior close of $11.64.
- The primary catalyst was third-quarter earnings: revenue beat estimates, but EPS of $0.05 missed the $0.09 consensus.
- A secondary driver was profit-taking after a roughly 4.4% pre-earnings rally into the report.
- Broader context: a small-cap medical-device name that remains well below its 52-week high amid a choppy 2026.
- News Significance Score: 36/100 — a moderate earnings miss on a move about 2.9 times the stock's typical daily swing.
- Traders are watching management's raised full-year guidance, OCD coil adoption, and the SWIFT protocol rollout.
- For more detail, explore the company's Price Targets, Earnings, and Forecast pages, and browse Trending AI Robots for active trading strategies.
Opening Summary
BrainsWay Ltd. (BWAY), an Israel- and U.S.-based neurotechnology company that develops the Deep Transcranial Magnetic Stimulation (Deep TMS) platform for treating mental health disorders, saw its shares fall 6.19% on November 10, closing the session around $10.92 versus a prior close of $11.64. The decline followed the release of third-quarter 2026 results, in which a top-line beat was overshadowed by an earnings-per-share miss, prompting investors to sell the news after a run-up into the report.
Earnings Results
The dominant catalyst was BWAY's third-quarter earnings release. Revenue rose 34% year over year to $18.1 million, edging past the roughly $17.8 million consensus, while operating income climbed 107% to $2.6 million and adjusted EBITDA increased 92% to $3.9 million. Management also said full-year 2026 results should land at the upper end of its prior guidance range. Despite these positives, the bottom line disappointed: the company reported EPS of $0.05, $0.04 below the $0.09 analysts had expected. In a small-cap name trading at a premium valuation, that per-share miss proved decisive, and the stock responded by giving up the prior session's gains.
Profit-Taking After a Pre-Earnings Rally
The earnings-driven move was amplified by positioning. Shares of BWAY had rallied roughly 4.4% into the report, rising from about $11.15 to $11.64, as investors anticipated the release. When the headline EPS figure came in light, a "sell the news" dynamic took hold, with short-term traders locking in gains rather than holding through the mixed print. The stock's longer-term backdrop adds context: it is down roughly 28% over the past three months and sits well below its 52-week high, making the stock vulnerable to sharp, sentiment-driven reversals on any headline disappointment.
Market Context and Trading Activity
The decline occurred in a quiet tape for the broader healthcare and small-cap space, suggesting the move was company-specific rather than a sector or macro event. BWAY typically trades around 100,000 shares a day, and the earnings session saw active turnover consistent with a catalyst-driven move. The 6.19% drop was unusually large relative to the stock's own recent history — its average daily swing over the prior 60 sessions was roughly 2.2%, and none of those sessions recorded an absolute move as large as today's. Technically, the decline pushed the stock back below the low-$11 level where it had consolidated in recent weeks.
News Significance Score
On a scale where 0 reflects no meaningful news combined with a move that is normal for the stock, and 100 reflects transformative news combined with an extreme, rare price move, today's action lands at 36 out of 100. The verified news — a mixed earnings report with an EPS miss offset by a revenue beat and raised guidance — is moderate in materiality relative to the company's roughly $440 million market capitalization. The price move was more unusual: at about 2.9 times the stock's typical daily swing, it was larger than any single session in the prior 60 trading days. The combination of a moderate catalyst and a notably outsized but not extreme move produces the score of 36.
What Comes Next for BWAY
Looking ahead, investors will focus on whether BWAY can sustain its revenue momentum and convert it into stronger bottom-line results. Key items to watch include fourth-quarter and full-year guidance execution, continued growth in OCD coil sales, and the rollout of the FDA-cleared accelerated SWIFT protocol. The company's recently announced strategic collaboration with Mindful Health Solutions and its growing installed base of roughly 2,080 systems are longer-term growth levers. Risks include competitive pressure in the neuromodulation market, reimbursement dynamics, and the stock's demonstrated tendency toward outsized swings on headline news.
Trending AI Robots
Tickeron's Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, and only those demonstrating the best recent performance are featured in this curated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. Visit Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BWAY's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BWAY turned positive on October 19, 2026. Looking at past instances where BWAY's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BWAY's RSI Indicator exited the oversold zone, 16 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 57 cases where BWAY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
Following a +9.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where BWAY advanced for three days, in 219 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
BWAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BWAY as a result. In 82 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BWAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for BWAY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. BWAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BWAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.666) is normal, around the industry mean (4.142). P/E Ratio (44.600) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of deep transcranial magnetic stimluation systems, novel, noninvasive medical devices
Industry MedicalNursingServices
Advertisement